<SEC-DOCUMENT>0001178913-24-000033.txt : 20240103
<SEC-HEADER>0001178913-24-000033.hdr.sgml : 20240103
<ACCEPTANCE-DATETIME>20240103070016
ACCESSION NUMBER:		0001178913-24-000033
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240103
FILED AS OF DATE:		20240103
DATE AS OF CHANGE:		20240103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		24504327

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2430725.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><br>
          <font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED
            STATES</font></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</font><br>
        Washington, D.C. 20549</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">
        <div style="text-align: center; line-height: 1.25;">FORM 6-K</div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>
        UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">For the month of January 2024</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Commission File Number 001-38807</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">CHEMOMAB THERAPEUTICS LTD.</font><br>
        (Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font> Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This Report of Foreign Private Issuer on Form 6-K (the &#8220;Form 6-K&#8221;) is being furnished by Chemomab Therapeutics Ltd. (the &#8220;Company&#8221;)
        for the purpose of furnishing, as Exhibit 99.1 to this Form 6-K, a press release, dated January 3, 2024, titled &#8220;Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected
        Topline Readout to Midyear 2024&#8221;.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Exhibit 99.1 to this Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form F-3 (File No.
        333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868).</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb88b6f2d81444427a9746627d922d3d9" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 8%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>Exhibit</u></div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>Description</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="exhibit_99-1.htm">99.1</a></div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="exhibit_99-1.htm">Press release, dated
                  January 3, 2024, titled &#8220;Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024&#8221;</a></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
        be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z274d8adc69ce4055bddc3022834bf229" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            </td>
            <td style="width: 20%; vertical-align: top;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 27%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: top;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Date: January 3, 2024</div>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td nowrap="nowrap" style="width: 27%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">/s/ Sigal Fattal</div>
            </td>
            <td nowrap="nowrap" style="width: 20%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 27%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Sigal Fattal</div>
            </td>
            <td nowrap="nowrap" style="width: 20%; vertical-align: bottom;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 27%; vertical-align: top;">
              <div style="line-height: 1.25;">Chief Financial Officer</div>
            </td>
            <td style="width: 20%; vertical-align: top;" colspan="1">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><img width="260" height="73" src="image00002.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">
        <div style="text-align: center; line-height: 1.25;">Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary </div>
        <div style="text-align: center; line-height: 1.25;">Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Mid-Year 2024</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8212;Expected Topline Data Readout Accelerated to Mid-Year 2024 Following Early Completion of Patient </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8212;CM-101&#8217;s Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">in PSC, Which Often Results in Liver Transplant or Death and Lacks Any FDA-Approved Treatments&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">TEL AVIV, Israel </font>&#9472; <font style="font-weight: bold;">January 3, 2024 &#9472;</font> Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet
          need, today announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis (PSC). The company also announced that it expects to report topline data from the
        PSC clinical trial by mid-year 2024, rather than in the second half of 2024 as previously projected.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">&#8220;We are delighted we were able to accelerate our expected topline PSC clinical data milestone to mid-year 2024 as a result of early
        completion of patient enrollment in this critical Phase 2 trial,&#8221; said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. &#8220;We believe that CM-101 has the potential for disease-modifying activity in PSC, a
        severe fibro-inflammatory liver disease that has no FDA-approved therapies. We anticipate that positive data from this 68-patient clinical trial would be a major catalyst for Chemomab and allow us to move towards a registrational trial in PSC.
        Positive data would also set the stage for advancing CM-101 in other fibro-inflammatory diseases such as systemic sclerosis, where we have an open U.S. IND to conduct a Phase 2 clinical trial.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which in preclinical and clinical studies has
        been associated with key pathways underlying PSC pathophysiology. CM-101&#8217;s dual anti-inflammatory and anti-fibrotic activity has demonstrated disease modifying potential in PSC and other fibro-inflammatory disorders. CM-101 has Orphan Drug
        designation for PSC in the U.S. and the European Union (EU) and was recently awarded Fast Track designation by the U.S. Food &amp; Drug Administration (FDA).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Chemomab Chief Medical Officer Matt Frankel, MD, added, &#8220;We appreciate the diligent work of our clinical and medical teams and our
        collaborators at medical centers around the world who completed enrollment in the PSC trial ahead of projections, as well as the commitment of the many patients and advocacy organizations who contributed to the success of the study to date. We are
        gratified at the high level of interest the SPRING trial has generated among patients and physicians, highlighting the urgent need for effective PSC therapies.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Chemomab&#8217;s Phase 2 SPRING trial (<u>NCT04595825</u>) is a double-blind, placebo-controlled, multiple dose study assessing
          the safety and tolerability of CM-101 administered to PSC patients with established large duct disease. The trial has completed enrollment of the planned 68 patients in the U.S., EU and Israel. Enrolled patients receive either 10 mg/kg or 20
          mg/kg of CM-101 or placebo via an intravenous infusion every three weeks over 15 weeks. The SPRING trial includes an open label extension available to all study participants, who receive infusions of either 10 mg/kg or 20 mg/kg of CM-101
        every three weeks for an additional 33 weeks. In addition to safety, the trial is measuring a wide range of secondary outcomes including serum biomarkers and physiological
          parameters. These include well-validated liver biomarkers such as alkaline phosphatase (ALP), ELF and PRO-C3, as well as FibroScan assessments of liver stiffness.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">About CM-101</font><br>
        CM-101 is a monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to many fibro-inflammatory
          diseases. CCL24's role as a therapeutic target has been validated in extensive preclinical studies and Chemomab researchers have demonstrated preclinical proof-of-concept for CM-101 in multiple animal and patient sample studies. CM-101 was safe
          and well tolerated in Phase 1 and Phase 2 clinical trials to date. In a Phase&#160;1b&#160;study it improved liver biomarkers, decreased liver stiffness and demonstrated a favorable PK and target engagement profile in patients with nonalcoholic fatty liver
          disease (NAFLD). Data from a completed Phase 2a liver fibrosis trial in nonalcoholic steatohepatitis (NASH) patients (<u>NCT05824156</u>) reported in 2023 showed consistent, positive improvements in key inflammatory and fibrogenesis-related biomarkers, including several that may serve as a potential bridge to
          activity in PSC. CM-101 has received Orphan Drug designation from the FDA and the EU&#8217;s EMA, along with FDA Fast Track status.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About Primary Sclerosing Cholangitis</div>
      <div style="line-height: 1.25;">PSC is a rare, progressive liver disease, characterized by inflammation and fibrosis (scarring) of the bile ducts. Eventually, it can
        lead to cirrhosis of the liver and liver failure. PSC also increases the risk of various cancers, which account for about half of PSC deaths. PSC affects an estimated 30,000 patients in the U.S. and about 80,000 worldwide. The disease can occur in
        all ages, genders and races, but is more common in men and is typically diagnosed in patients in their 40s. The underlying cause of PSC is unknown, but about 75% of individuals with PSC also have inflammatory bowel disease. Currently there are no
        FDA or EMA-approved therapies for patients with PSC. Liver transplantation is common in advanced cases, but even then, PSC re-occurs in about 20% of transplanted patients. There is a high unmet need for therapeutic options to address the symptoms
        and modify the progression of this devastating illness.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
      <div style="line-height: 1.25;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These
        forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the expectation that Chemomab will report topline data from the PSC clinical trial by mid-year 2024; the length, duration and
        impact of the war in Israel on Chemomab&#8217;s business and operations; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of
        Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and
        conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking
        statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of
        Chemomab could differ materially from those described in or implied by the statements in this presentation, including those found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly
        disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or
        circumstances on which any such statements are based, except as required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;">Chemomab is a clinical stage biotechnology company
          developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24
          activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in
          patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. The CM-101 program for the treatment of systemic sclerosis is Phase
          2-ready. A Phase 2 trial in primary sclerosing cholangitis patients has completed patient enrollment, with topline data expected in mid-year 2024. For more information about Chemomab, visit <u>chemomab.com</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Contacts:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Media and Investors</font>:</div>
      <div style="line-height: 1.25;">Barbara Lindheim</div>
      <div style="line-height: 1.25;">Consulting Vice President, Investor &amp; Public Relations, Strategic Communications</div>
      <div style="line-height: 1.25;">Phone: +1 917-355-9234</div>
      <div style="line-height: 1.25;"><u>barbara.lindheim@chemomab.com</u></div>
      <div style="line-height: 1.25;"><u>IR@chemomab.com</u></div>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #M T8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ[GV ->J:7^SY8K&IU?6[B60]5M$5 /Q;=G\A78UAJ.CW^\Q3JSV/-Q\5O'
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MO^PG)_Z*BKU6O*O@#_R(E]_V$Y/_ $5%7JM<^(_BR-*?P(*RO$__ "*>L_\
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M_$'C &"YF6VL,Y%I;Y"G_>/5OQX]A6M\-OAQ/XB=]9U.%DT>W5F0.,?:7 X
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M)Y);MIPT.< %$7'('/RFNRHHJ92<I<S&DDK(*I:O9OJ.BW]C&RJ]S;R0JS=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6UC:QVMI!%!;Q#:D42!54>P'2NBMC%*/+#J9PHM.[)J***\XZ0HHHH ****
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'HHHK(H__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
